SSR240612
目录号 : GC19339
SSR240612是一种新的、有效的、具有口服活性的特异性非肽慢激肽B1受体拮抗剂，可抑制Lys0-desAr9-BK (10nM) 诱导的人成纤维细胞MRC5中肌醇单磷酸的形成，IC50为1.9nM。
Cas No.:464930-42-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SSR240612 is a new, potent, and orally active specific non-peptide bradykinin B1 receptor antagonist, which inhibited Lys0-desAr9-BK (10nM)-induced inositol monophosphate formation in human fibroblast MRC5, with an IC50 of 1.9nM[1]. Bradykinin B1 Receptor (B1R) is a G-protein-coupled receptor with low expression level in normal tissues, but it can be induced to express in pathological states such as inflammation, diabetes, ischemia/reperfusion injury, and participate in inflammation and pain signal transmission[2]. SSR240612 displaced the binding of [3H]Lys0-des-Arg9-BK to the B1 receptors in human fibroblast MRC5 and to recombinant human B1 receptor expressed in human embryonic kidney cells with inhibition constants (Ki ) of 0.48 and 0.73nM, respectively. The affinity of SSR240612 for B2 receptors labeled with [3H]BK was much lower with a Ki of 481nM for guinea pig ileum membranes and a Ki of 358nM for membrane preparations of CHO cells expressing human B2 receptors[1]. SSR240612 is usually used for research in inflammatory, immune, and metabolic diseases[3][4][5].
In vitro, treatment of M. tuberculosis-infected RAW 264.7 cells with SSR240612 (10μM) for 4 days displayed a marked inhibitory effect on CFU counts[6].
In vivo, oral administration of SSR240612 (10 and 30mg/kg) for 3h blocked tactile and cold allodynia without affecting plasma glucose and insulin, insulin resistance (HOMA index) and aortic superoxide anion production in glucose-fed rat compared with control rat[7].
References:
[1] Gougat, J., Ferrari, B., Sarran, L., Planchenault, C., Poncelet, M., Maruani, J., Alonso, R., Cudennec, A., Croci, T., Guagnini, F., Urban-Szabo, K., Martinolle, J. P., Soubrié, P., Finance, O., & Le Fur, G. (2004). SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. The Journal of pharmacology and experimental therapeutics, 309(2), 661–669.
[2] Campos, M. M., Leal, P. C., Yunes, R. A., & Calixto, J. B. (2006). Non-peptide antagonists for kinin B1 receptors: new insights into their therapeutic potential for the management of inflammation and pain. Trends in pharmacological sciences, 27(12), 646–651.
[3] Tidjane, N., Hachem, A., Zaid, Y., Merhi, Y., Gaboury, L., Girolami, J. P., & Couture, R. (2015). A primary role for kinin B1 receptor in inflammation, organ damage, and lethal thrombosis in a rat model of septic shock in diabetes. European journal of inflammation, 13(1), 40–52.
[4] Costa, R., Fernandes, E. S., Menezes-de-Lima, O., Jr, Campos, M. M., & Calixto, J. B. (2006). Effect of novel selective non-peptide kinin B(1) receptor antagonists on mouse pleurisy induced by carrageenan. Peptides, 27(11), 2967–2975.
[5] El Akoum, S., Haddad, Y., & Couture, R. (2017). Impact of pioglitazone and bradykinin type 1 receptor antagonist on type 2 diabetes in high-fat diet-fed C57BL/6J mice. Obesity science & practice, 3(3), 352–362.
[6] Rodrigues-Junior, V. S., Pail, P. B., Villela, A. D., Falcão, V. C. A., Dadda, A. S., Abbadi, B. L., Pesquero, J. B., Santos, D. S., Basso, L. A., & Campos, M. M. (2018). Effect of the bradykinin 1 receptor antagonist SSR240612 after oral administration in Mycobacterium tuberculosis-infected mice. Tuberculosis (Edinburgh, Scotland), 109, 1–7.
[7] Dias, J. P., Ismael, M. A., Pilon, M., de Champlain, J., Ferrari, B., Carayon, P., & Couture, R. (2007). The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. British journal of pharmacology, 152(2), 280–287.
SSR240612是一种新的、有效的、具有口服活性的特异性非肽慢激肽B1受体拮抗剂，可抑制Lys0-desAr9-BK (10nM) 诱导的人成纤维细胞MRC5中肌醇单磷酸的形成，IC50为1.9nM[1]。缓激肽B1受体（Bradykinin B1 Receptor, B1R）是一种G蛋白偶联受体，在正常组织中表达水平较低，但在炎症、糖尿病、缺血/再灌注损伤等病理状态下可诱导表达，参与炎症和疼痛信号传递[2]。SSR240612抑制了[3H]Lys0-des-Arg9-BK与人成纤维细胞MRC5中B1受体和人胚胎肾细胞中表达的重组人B1受体的结合，抑制常数（Ki）分别为0.48和0.73nM。SSR240612对[3H]BK标记的B2受体的亲和力更低，对豚鼠回肠膜的Ki为481nM，对表达人B2受体的CHO细胞的膜制剂的Ki为358nM[1]。SSR240612通常用于炎症、免疫和代谢性疾病的研究[3][4][5]。
在体外，10μM SSR240612 处理感染结核分支杆菌的RAW 264.7细胞4天可显著抑制CFU计数[6]。
在体内，与对照大鼠相比，口服SSR240612(10和30mg/kg) 3h可阻断葡萄糖喂养大鼠的触觉和冷痛觉，而不影响血糖和胰岛素、胰岛素抵抗（HOMA指数）和主动脉超氧阴离子生成[7]。
| Cell experiment [1]: | |
Cell lines | RAW 264.7 cells |
Preparation Method | RAW 264.7 cells were infected with M. tuberculosis H37Rv for 3 h, followed by washing extracellular bacteria. The cells were then treated with the tested substances in DMEM medium: BK (3nM), des-Arg9 -BK (30nM), HOE-140 (1μM), and SSR240612 (10μM). After 4 days, macrophages were then lysed with 0.025% SDS, and these suspensions were diluted and plated on Middlebrook 7H10 Agar containing OADC, prior to CFU counting. |
Reaction Conditions | 10μM; 4 days |
Applications | SSR240612 displayed a marked inhibitory effect on CFU counts. |
| Animal experiment [2]: | |
Animal models | Young male Sprague–Dawley rats |
Preparation Method | SSR240612 was administered orally to rats fed D-glucose for 12 weeks, which displayed consistent symptoms of sensory abnormalities. The effects of four doses (0.3, 3.0, 10 and 30mg/kg) of SSR240612 were determined on allodynia at 1, 3, 6, 24, and 48h post-gavage. SSR240612 was administered orally at the dose of 10mg/kg to rats treated for 12 weeks with glucose (n= 8). Rats were fasted overnight and killed by CO2 asphyxia at 6h post-gavage, and then the blood and thoracic aorta were collected for the measurement of plasma levels of glucose and insulin and the determination of superoxide anion, respectively. |
Dosage form | 0.3, 3.0, 10 and 30mg/kg;1, 3, 6, 24, and 48h; p.o. |
Applications | SSR240612 blocked tactile and cold allodynia at 3h (ID50 = 5.5 and 7.1mg/kg,respectively) in glucose-fed rats but had no effect in control rats. The antagonist (10mg/kg) had no effect on plasma glucose and insulin, insulin resistance (HOMA index) and aortic superoxide anion production in glucose-fed rats. |
References: | |
| Cas No. | 464930-42-5 | SDF | |
| Canonical SMILES | O=S(N[C@@H](C1=CC=C2C(OCO2)=C1)CC(N[C@@H](C(N(C)C(C)C)=O)CC3=CC=C(CN([C@@H]4C)[C@H](CCC4)C)C=C3)=O)(C5=CC(C=CC(OC)=C6)=C6C=C5)=O.Cl[H] | ||
| 分子式 | C42H53ClN4O7S | 分子量 | 793.41 |
| 溶解度 | DMSO : ≥ 106.6 mg/mL (134.36 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.2604 mL | 6.3019 mL | 12.6038 mL |
| 5 mM | 0.2521 mL | 1.2604 mL | 2.5208 mL |
| 10 mM | 0.126 mL | 0.6302 mL | 1.2604 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet